A study designed to test a new oxygen delivery device (NHFO2) in patients with long term respiratory disease who require home oxygen.
- Conditions
- Chronic obstructive pulmonary disease (COPD)Interstitial lung diseaseBronchiectasisAny other doctor diagnosed chronic respiratory condition with requirement for long term oxygen therapy (LTOT)Respiratory - Chronic obstructive pulmonary diseaseRespiratory - Other respiratory disorders / diseases
- Registration Number
- ACTRN12617001278325
- Lead Sponsor
- Fisher and Paykel Healthcare Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 12
1) Adults over the age of 18 with a doctor’s diagnosis of a chronic respiratory disease, such as COPD, bronchiectasis or interstitial lung disease, who are prescribed long term oxygen therapy (LTOT).
2) Participant's SpO2 85-90% without oxygen.
3) Participant's respiratory condition must have been stable with no exacerbations within the last 4 weeks
1) Age <18
2) Any other condition which, at the investigator’s discretion, is believed may present a safety risk or impact the feasibility of the study or the study results.
3) Diagnosis of a notifiable disease
4) The presence of an implantable Medical Device
5) Inability to tolerate an interruption in oxygen therapy
6) Requirement for more than 4L/min LTOT at rest
7) Unstable angina or myocardial infarction within the previous month
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The percentage of total time spent within the participant's SpO2 within target range of 92 to 96% while using NHFO2 in autotitration mode. The SpO2 will be measured by the pulse oximeter associated with the NHFO2 device. Time in autotitration mode will be measured by a study investigator using a stopwatch.[End of each visit - approximately 3 hours]
- Secondary Outcome Measures
Name Time Method